Literature DB >> 1516159

Effects on the rabbit coronary artery of LP-805, a new type of releaser of endothelium-derived relaxing factor and a K+ channel opener.

M Nakashima1, T Akata, H Kuriyama.   

Abstract

In the rabbit epicardial coronary artery, 8-tert-butyl-6,7-dihydropyrolo[3,2-e]5-methylpyrazolo [1,5-a]pyrimidine-3-carbonitrile (LP-805, greater than 0.1 microM) hyperpolarized the muscle membrane in both proximal (diameter, 1-1.2 mm) and distal (diameter, 0.1-0.2 mm) regions of intact (+E) tissue, in which endothelium is present, and endothelium-denuded (-E) tissue. LP-805-induced hyperpolarization was inhibited by glibenclamide. In -E tissues in both regions, acetylcholine (ACh, greater than 0.1 microM) depolarized the membrane, and LP-805 inhibited the depolarization. However, in +E tissues, ACh (greater than 0.1 microM) transiently hyperpolarized the membrane that was not modified by glibenclamide (10 microM), charybdotoxin (100 nM), and NG-nitro-L-arginine (L-NNA, 100 microM). In -E tissues of both regions, LP-805 consistently inhibited the 10 microM ACh-induced contraction (IC50, 2.8 microM), and 10 microM glibenclamide shifted this concentration-response curve to the right (IC50, 20 microM). In +E tissues, LP-805 more potently inhibited the ACh-induced contraction (IC50, 0.3 microM), and this inhibition was prevented by L-NNA (100 microM) but not by indomethacin or glibenclamide (10 microM). In -E and +E tissues of both regions, LP-805 repolarized the high K(+)-induced depolarization (less than 20 mM) and relaxed the tissues precontracted by high K+ (less than 30 mM); these electrical and mechanical effects of LP-805 were prevented by glibenclamide (10 microM) in +E tissues. In +E tissues, the K(+)-induced contraction (less than 30 mM) was more strongly inhibited than in -E tissues, but after treatment with L-NNA, LP-805 relaxed -E and +E tissues precontracted to the same extent in the presence of high K+. LP-805 (10 microM) did not inhibit the Ca(2+)-induced contraction in skinned muscle tissues but did slightly inhibit the ACh-induced contraction in Ca(2+)-free solution containing 2 mM EGTA. Thus, LP-805 has a potent releasing action on endothelium-derived relaxing factor and also the potential to open the glibenclamide-sensitive K+ channel. These events would account for the dilation of the rabbit coronary artery exposed to LP-805.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516159     DOI: 10.1161/01.res.71.4.859

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Effects of heparin on the vasodilator action of protamine in the rabbit mesenteric artery.

Authors:  T Akata; K Kodama; S Takahashi
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

Review 3.  K channel openers activate different K channels in vascular smooth muscle cells.

Authors:  K Kitamura; M Kamouchi
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

4.  The effects of a novel vasodilator, LP-805, on cytosolic Ca2+ concentrations and on tension in rabbit isolated femoral arteries.

Authors:  M Ushio-Fukai; K Hirano; H Kanaide
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

5.  Effect of LP-805, a releaser of endothelium-derived nitric oxide, on systemic vasodilatation in vivo.

Authors:  M Inazu; M Tujitani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

6.  A target K+ channel for the LP-805-induced hyperpolarization in smooth muscle cells of the rabbit portal vein.

Authors:  M Kamouchi; S Kajioka; T Sakai; K Kitamura; H Kuriyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

7.  Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries.

Authors:  M Nakashima; J V Mombouli; A A Taylor; P M Vanhoutte
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.